S
Stéphanie Raymond
Researcher at French Institute of Health and Medical Research
Publications - 70
Citations - 1413
Stéphanie Raymond is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Tropism & Viral load. The author has an hindex of 19, co-authored 63 publications receiving 1239 citations. Previous affiliations of Stéphanie Raymond include University of Toulouse & Paul Sabatier University.
Papers
More filters
Journal ArticleDOI
Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism.
Stéphanie Raymond,Pierre Delobel,Maud Mavigner,Michelle Cazabat,Corinne Souyris,Karine Sandres-Sauné,Lise Cuzin,Bruno Marchou,Patrice Massip,Jacques Izopet +9 more
TL;DR: Genotypic predictions performed well in paired genotypic and phenotypic assessment of HIV-1 coreceptor usage and would make the clinical use of CCR5 antagonists easier.
Journal ArticleDOI
HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy
Maud Mavigner,Pierre Delobel,Pierre Delobel,Michelle Cazabat,Martine Dubois,Fatima-Ezzahra L'Faqihi-Olive,Stéphanie Raymond,Stéphanie Raymond,Christophe Pasquier,Christophe Pasquier,Bruno Marchou,Patrice Massip,Jacques Izopet,Jacques Izopet +13 more
TL;DR: The compartmentalization of the viruses between the plasma and the blood monocytes suggests at least two origins of residual virus production during effective cART, and suggests that low-level HIV-1 production in some patients may contribute to persistent immune dysfunction despite cART.
Journal ArticleDOI
CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression.
Stéphanie Raymond,Pierre Delobel,Maud Mavigner,Michelle Cazabat,Stéphanie Encinas,Corinne Souyris,Patrick Bruel,Karine Sandres-Sauné,Bruno Marchou,Patrice Massip,Jacques Izopet +10 more
TL;DR: Primary infection with CXCR4-using viruses was associated with an accelerated rate of disease progression, estimated by a faster decline of CD4+ T-cell count under 350 cells/μl and by a reduced delay in initiating a first antiretroviral treatment.
Journal ArticleDOI
Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage
Stéphanie Raymond,Pierre Delobel,Pierre Delobel,Maud Mavigner,Michelle Cazabat,Corinne Souyris,Stéphanie Encinas,Patrick Bruel,Karine Sandres-Sauné,Karine Sandres-Sauné,Bruno Marchou,Patrice Massip,Jacques Izopet,Jacques Izopet +13 more
TL;DR: A new recombinant virus phenotypic assay for determining HIV-1 tropism using both plasma and cell samples from patients who are candidates for treatment with CCR5 antagonists is validated.
Journal ArticleDOI
Evaluation of the Genotypic Prediction of HIV-1 Coreceptor Use versus a Phenotypic Assay and Correlation with the Virological Response to Maraviroc: the ANRS GenoTropism Study
Patricia Recordon-Pinson,Cathia Soulié,Philippe Flandre,Diane Descamps,Mouna Lazrek,Charlotte Charpentier,Brigitte Montes,Mary-Anne Trabaud,Jacqueline Cottalorda,Véronique Schneider,Laurence Morand-Joubert,Catherine Tamalet,Delphine Desbois,Muriel Macé,Virginie Ferré,Astrid Vabret,Annick Ruffault,Coralie Pallier,Stéphanie Raymond,Jacques Izopet,Jacques Reynes,Anne-Geneviève Marcelin,Bernard Masquelier +22 more
TL;DR: There were strong arguments in favor of using genotypic coreceptor use assays for determining which patients would respond to CCR5 antagonist.